IP Library Granted Patent US 10,370,353
Granted Patent B2
US 10,370,353 · App. 15/835,991 · Granted Aug 6, 2019

Antifungal compounds and processes for making

Inventors: William J. Hoekstra (Durham, NC); David Dale Wirth (Oak Ridge, NC); Tracy Ehiwe (Cambridge, GB); Thierry Bonnaud (Cambridge, GB)
Assignee: Mycovia Pharmaceuticals, Inc.
C07D401/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,370,353
App. No.
15/835,991
Granted
Aug 6, 2019
Kind
B2
Abstract

The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for preparing polymorphs of compound 1 and substituted derivatives thereof.

Claims (15)

1. A 1.5 hydrate polymorph of a compound of formula 1,

characterized by at least one of:

(i) a powdered X-ray diffraction pattern having two or more peaks expressed in degrees 2-theta±0.2° and selected from peaks delineated in the pattern of FIG. 5 ; or

(ii) a DSC thermogram showing an endotherm at about 85° C.

2. A process to prepare a 1.5 hydrate polymorph of compound 1:

comprising suspending a compound of formula 1 in a solvent and isolating any solid material.

3. The compound of claim 1 , characterized by a powdered X-ray diffraction pattern having peaks expressed in degrees 2-theta±0.2° at each of about 7.9, 8.9, 16.2, 22.6, 24.2, 26.6, 28.0.

4. The compound of claim 1 , wherein the compound is essentially solvent free.

5. The compound of claim 1 , wherein the compound has 0.1-0.5% weight solvent.

6. The process of claim 2 , wherein the compound suspended in the solvent is in one of an amorphous, solvate, or hydrate form.

7. The process of claim 2 , wherein the solvent is an organic solvent.

8. The process of claim 2 , wherein the solvent is a C 3 -C 10 alcohol.

9. The process of claim 2 , comprising two or more solvents.

10. The process of claim 2 , wherein one solvent is a C 3 -C 10 alcohol and one solvent is water.

11. The process of claim 2 , wherein the isolated solid material is dried at a temperature of 30-60° C.

Assignments (5)
CHANGE OF NAME Recorded Apr 3, 2019
From: VIAMET PHARMACEUTICALS (NC), INC.
To: MYCOVIA PHARMACEUTICALS, INC.
Reel/Frame 048781/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: HOEKSTRA, WILLIAM J.; WIRTH, DAVID DALE
To: VIAMET PHARMACEUTICALS, INC.
Reel/Frame 044811/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: EHIWE, TRACY; BONNAUD, THIERRY
To: JOHNSON MATTHEY PLC.
Reel/Frame 044811/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: JOHNSON MATTHEY PLC.
To: VIAMET PHARMACEUTICALS, INC.
Reel/Frame 044811/0747 →
CHANGE OF NAME Recorded Jan 2, 2018
From: VIAMET PHARMACEUTICALS, INC.
To: VIAMET PHARMACEUTICALS (NC), INC.
Reel/Frame 044978/0893 →
Continuity (3)
Division 15317006
Provisional Application 62135682 · Mar 19, 2015
Related Publication 20180319768A1 · Nov 8, 2018